2025
POS0015 Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors
Mehrotra S, Sano Y, Wilson E, Durairaj C, Kong K, Xia G, Dunbar F, Halkowycz P, Spector T, Bunick C, McInnes I. POS0015 Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors. Annals Of The Rheumatic Diseases 2025, 84: 333. DOI: 10.1016/j.ard.2025.05.412.Peer-Reviewed Original ResearchBaricitinib 4 mgJanus kinase inhibitorsTyrosine kinase 2Plasma concentrationsTreatment of immune-mediated inflammatory diseasesJanus kinaseImmune-mediated inflammatory diseasesInhibition of tyrosine kinase 2Published population pharmacokinetic modelTyk2-mediated signalingTyrosine kinase 2 inhibitionLate-stage clinical developmentPopulation pharmacokinetic modelTyrosine kinase 2 inhibitorWhole blood culturesDrug plasma concentrationsTYK2 inhibitionInhibition of Janus kinaseIL-12/18Approved doseClinical doseIFN-gDeucravacitinibHealthy volunteersIL-2Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib
Mostaghimi A, Craiglow B, King B, Shapiro J, Ko J, Tosti A, Ohyama M, Brogan Y, Yu G, Sontag A, Somani N. Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib. British Journal Of Dermatology 2025, ljaf088. PMID: 40179237, DOI: 10.1093/bjd/ljaf088.Peer-Reviewed Original ResearchBaricitinib 4 mgBaricitinib 2 mgHair-bearing sitesAlopecia areataResponse rateBenefit of baricitinibTreated with baricitinibRandomised to placeboPlacebo-controlled trialResponse to treatmentScalp hair lossSALT scoreDouble-blindClinical presentationBaricitinib treatmentTreatment successHair regrowthBaricitinibBaseline severityPatientsClinician reportsHair lossPlaceboPooled dataScalpCharacterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Senna M, Taylor S, Piraccini B, Shapiro J, Somani N, Jedynak J, Ogwu S, Buchanan A, Craiglow B, Ohyama M. Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s522. DOI: 10.25251/skin.9.supp.522.Peer-Reviewed Original ResearchSeverity of Alopecia ToolLoss of responseSeverity of Alopecia Tool scoreBaricitinib 4 mgLost responseMaintenance treatmentAlopecia areataLong-term maintenance therapyYears of initial treatmentWeeks of maintenance treatmentBaseline disease characteristicsSevere alopecia areataPhase 3 trialYear of treatmentPost Hoc AnalysisBaricitinib monotherapySevere AAMaintenance therapySALT scoreMaintained responseInitial treatmentBaseline characteristicsAdjunctive therapyTreatment responseCOVID-19 infection
2024
Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 14: 1959-1968. PMID: 38904749, PMCID: PMC11265044, DOI: 10.1007/s13555-024-01208-x.Peer-Reviewed Original ResearchSymptoms of anxietyQuality of lifeDomain scoresHealth-related quality of lifeMeasures of quality of lifeMeasures of HRQOLHealth-related qualityBaricitinib 2 mgSALT scoreBaricitinib 4 mgPsychosocial distressAssociated with improvementsHair regrowthAA scaleMethodsThis post hoc analysisHRQoLDose of baricitinibInterquartile rangePhase III trialsResultsIn totalSevere alopecia areataPost Hoc AnalysisDisease associated with high ratesDepressionScores
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply